Thomson Reuters Launches IDRAC(R) Notes

New Commenting Feature Facilitates Increased Collaboration With Colleagues

PHILADELPHIA and LONDON, March 23 /PRNewswire/ — The Healthcare and Science business of Thomson Reuters has launched IDRAC(R) Notes, an add-on commenting feature to IDRAC. This will allow colleagues within the same organization to create, update and share comments attached to IDRAC PDF documents.

Designed from user feedback, IDRAC Notes improves collaboration and communication on regulatory affairs matters and improves information sharing and interpretation of regulatory requirements.

“Users rely on IDRAC to keep up with ever-changing regulatory requirements,” said Claude Basset, VP Specialty Markets at Thomson Reuters. “With the addition of IDRAC Notes, they now have the ability to capture, edit and share internal knowledge in a quick, easy and secure process.”

IDRAC, the regulatory intelligence solution of choice for the global pharmaceutical industry, allows organizations to get products to market faster and minimize regulatory risk by providing trusted information and analysis on the most up-to-date regulatory requirements.

For more information on IDRAC, please visit http://www.thomsonreuters.com/products_services/scientific/IDRAC.

About Thomson Reuters

Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.

SOURCE Thomson Reuters